Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31

You may also be interested in...



Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK

PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago

Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK

PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago

Cash-pretty Australian Biotech Biota Returns $20 Million To Shareholders

PERTH, Australia - Just days after unveiling positive results from Phase III trials on its second-generation flu treatment laninamivir, co-developed with Daiichi Sankyo, Aussie Biotech Biota announced Aug. 13 that it would issue AU$20 million to its shareholders

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel